non-muscle-invasive bladder cancer News
-
GeneCentric to Present Initial Clinicogenomic Results from the GARNER High-Risk Non-Muscle Invasive Bladder Cancer Real-World Study
Durham, NC, May 10, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American Urological Association (AUA) Annual Meeting, which is being held in New ...
-
UroGen Pharma to Present at Upcoming Conferences
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare conferences in January: 40th Annual J.P. Morgan Healthcare Conference Thursday, January 13 at 9:45 a.m. ET HC Wainwright BioConnect Conference ...
-
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced the initiation of its Phase 3 ENVISION study of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). ENVISION is a single-arm, ...
-
First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
Study explores opportunity to shift from clinic to home instillation of this promising non-surgical treatment Potential to transform care and access to treatment for this growing patient population UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that the ...
-
Nucleix’s BE Safe @Home Project Brings Bladder Cancer Surveillance to Patients’ Homes During COVID-19 Pandemic and Beyond
-Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, recently announced the launch of its BE Safe @Home project to bring surveillance for recurrence of non-muscle invasive bladder cancer (NMIBC) to patients’ homes with its Bladder EpiCheck® urine test. This initiative was developed after consulting with world-leading urologists in an ...
By Nucleix Ltd.
-
UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an overview of the Company’s recent developments. “2020 was a pivotal year for UroGen with the launch of ...
-
Nucleix’s BE Safe @Home Project Brings Bladder Cancer Surveillance to Patients’ Homes During COVID-19 Pandemic and Beyond
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, recently announced the launch of its BE Safe @Home project to bring surveillance for recurrence of non-muscle invasive bladder cancer (NMIBC) to patients’ homes with its Bladder EpiCheck® urine test. This initiative was developed after ...
By Nucleix Ltd.
-
OncoDiag raises €2.5M ($3M) to develop its diagnostic testing for early detection of cancer
OncoDiag, a company specializing in the development of diagnostic tests for the early detection of cancer, today announces that it has raised €2.5 million ($3M) in a Series A round of funding. Of this, €1.5 million ($1.8M) was from several groups of business angels, including a number of historic investors: Angels Santé, Business Angels des Grandes Ecoles (BADGE), and Normandie ...
By OncoDiag
-
Alternating Nucleix’s Bladder EpiCheck® With Standard Surveillance Can Reduce Burden on Patients and Healthcare Systems
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced the publication of an analysis highlighting that Bladder EpiCheck® can reduce both patient burden and healthcare system costs in the U.S. and European countries for low grade intermediate risk non-muscle invasive bladder cancer ...
By Nucleix Ltd.
-
Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients
SAN DIEGO & REHOVOT, ISRAEL--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology (EAU) Virtual Congress. The first abstract titled, “Real world evidence of alternating cystoscopy/cytology ...
By Nucleix Ltd.
-
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto® (mitomycin) for pyelocalyceal solution administration in the Journal of Urology online on February 7, 2022. This report provides a stepwise ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you